Skip to Content

Join the 'Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery' group to help and get support from people like you.

Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery News

Knee Replacement Patients May Be Able to Hit the Shower Sooner

Posted 27 May 2016 by Drugs.com

THURSDAY, May 26, 2016 – Knee surgery patients are usually instructed to wait two weeks after surgery to take a shower to reduce the risk of infection. But a small new study suggests this may not be necessary. Researchers found no differences in bacterial swabs from those who waited two weeks to shower compared with those allowed to shower after about two days. That's no doubt welcome news to the many patients who've struggled to find a way to bathe without getting their incision wet. The study, led by Dr. Harold Rees, an orthopaedic surgeon at Loyola University Medical Center in Maywood, Ill., followed 32 patients. Half were randomly assigned to shower after two weeks. The other half could shower as soon as their surgical dressing was removed – typically two days after surgery. None of the patients developed a post-operative infection, the study found. And, unsurprisingly, patients ... Read more

Related support groups: Surgery, Knee Joint Replacement, Orthopedic Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery

Health Tip: Know Your Risk for Deep Vein Thrombosis

Posted 4 Aug 2015 by Drugs.com

-- A dangerous condition called deep vein thrombosis (DVT) occurs when a blood clot develops in a vein deep inside the body. The U.S. National Heart Lung and Blood Institute mentions these potential risk factors: Having had a previous DVT, or taking medication that thickens the blood or promotes clotting. Having had surgery, a broken bone or other injury that affects a deep vein. Having reduced blood flow to a deep vein as a result of inactivity. Typical causes are post-surgical recovery, or taking a long trip that limits your ability to move around. Being pregnant. Being treated for cancer. Having a central venous catheter. Being over the age of 60, being a smoker or being obese. Read more

Related support groups: Blood Disorders, Warfarin, Coumadin, Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Lovenox, Eliquis, Deep Vein Thrombosis, Heparin, Deep Vein Thrombosis - First Event, Deep Vein Thrombosis - Recurrent Event, Rivaroxaban, Enoxaparin, Apixaban, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Fragmin, Clexane, Arixtra, Hep-Pak

FDA Approves Eliquis to Reduce Risk of Blood Clots Following Hip Or Knee Replacement Surgery

Posted 18 Mar 2014 by Drugs.com

PRINCETON, N.J. & NEW YORK-- Friday, March 14, 2014 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. “Today’s FDA approval of Eliquis for DVT prophylaxis in patients who have undergone hip or knee replacement is a significant milestone for this important medicine, which is also approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation,” said Brian Daniels, M.D., senior vice president, global development and medical affairs, Bristol-Myers Squibb. “This approval reflects the continued commitment of the allianc ... Read more

Related support groups: Eliquis, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Apixaban, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery

Diabetes Doesn't Seem to Raise Risks After Knee Replacement

Posted 27 Feb 2013 by Drugs.com

WEDNESDAY, Feb. 27 – People with diabetes who undergo knee replacement surgery are not at greater risk for infection, deep vein thrombosis (a type of blood clot), or other complications following the procedure than people without diabetes, new study findings indicate. "This current study suggests that patients with diabetes who have higher glucose [blood sugar] levels may not be at greater risk of poor surgical outcomes," explained study author Annette Adams, of the Kaiser Permanente Southern California Department of Research and Evaluation. "There appear to be other factors at play, and patients and their providers need to consider multiple factors, including but not limited to diabetes status, as they make decisions about whether to have this surgery," she added in a news release from the American Academy of Orthopaedic Surgeons. For the study, the researchers examined the records of ... Read more

Related support groups: Diabetes, Type 2, Knee Joint Replacement, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery

FDA Expands Use of Xarelto to Treat, Reduce Recurrence of Blood Clots

Posted 2 Nov 2012 by Drugs.com

November 2, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment. Blood clots occur when blood thickens and clumps together. DVT is a blood clot that forms in a vein deep in the body. Most deep vein blood clots occur in the lower leg or thigh. When a blood clot in a deep vein breaks off and travels to an artery in the lungs and blocks blood flow, it results in a potentially deadly condition called PE. Xarelto is already FDA-approved to reduce the risk of DVTs and PEs from occurring after knee or hip replacement surgery (July 2011), and to reduce the risk of stroke in people who have a type of abnormal heart rhythm called non-valvular atrial fibrillation (November 2011). The FDA reviewed ... Read more

Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Deep Vein Thrombosis, Deep Vein Thrombosis - First Event, Deep Vein Thrombosis - Recurrent Event, Rivaroxaban, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Orthopedic Surgery, Deep Vein Thrombosis Prophylaxis after General Surgery

Joint Replacement Patients Face Blood Clot Risk in Hospital

Posted 17 Jan 2012 by Drugs.com

TUESDAY, Jan. 17 – One of every 100 people undergoing knee replacement surgery and 1 of 200 people having hip replacement surgery will develop a blood clot before they leave the hospital, even if they take steps to prevent the development of these blood clots, a new evidence review suggests. A deep venous thrombosis (DVT) or blood clot can form deep within the veins, usually in the leg. The real risk occurs if these blood clots dislodge, travel through your bloodstream, and block blood flow in your lungs, which is called pulmonary embolism. The new study, published in the Jan. 18 Journal of the American Medical Association, seeks to provide a reliable benchmark of this risk, but many experts in the field worry that the actual risk of blood clots after joint replacement is really much higher than this study suggests. Researchers led by Jean-Marie Januel, of the Lausanne University ... Read more

Related support groups: Hip Replacement, Knee Joint Replacement, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery

FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery

Posted 1 Jul 2011 by Drugs.com

Raritan, NJ (July 1, 2011) — Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. "The approval of once-daily Xarelto tablets will provide a new option to help protect patients from developing venous blood clots following knee or hip replacement surgery," said Louis M. Kwong, M.D., Professor of Orthopedic Surgery at Harbor-UCLA Medical Center, who was involved with the rivaroxaban clinical trials program in this indication. "Xarelto has a proven clinical benefit over one of today’s most widely used options in preventing these potentially life-threatening blood clots, and the use of a once-daily pill may pl ... Read more

Related support groups: Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery

Ask a Question

Further Information

Related Condition Support Groups

Deep Vein Thrombosis - Prophylaxis

Related Drug Support Groups

warfarin, Coumadin, Xarelto, Lovenox, Eliquis, rivaroxaban, enoxaparin, apixaban, Clexane, view more... Arixtra, Jantoven, fondaparinux, Lovenox HP, Arixtra 10 mg / dose, Arixtra 7.5 mg / dose, Arixtra 5 mg / dose, Clexane Forte